Talnetant GlaxoSmithKline.

Article Details

Citation
Copy to clipboard

Evangelista S

Talnetant GlaxoSmithKline.

Curr Opin Investig Drugs. 2005 Jul;6(7):717-21.

PubMed ID
16044668 [ View in PubMed
]
Abstract

Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.

DrugBank Data that Cites this Article

Drugs